destiny-gastric02: 2l t-dxd in her2 gastric cancers
Published 2 years ago • 136 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
1:58
destiny-gastric02: t-dxd as a second-line treatment for her2-positive gastric cancer
-
2:58
updated analysis of destiny-gastric02: t-dxd in her2 gej cancer who progressed with trastuzumab
-
1:34
destiny-gastric03: t-dxd in her2 and her2-low gastric cancer
-
3:25
considerations for molecular testing for her2 gastric cancer
-
4:41
destiny-gastric03: trastuzumab deruxtecan in her2-overexpressing gastric cancer
-
3:02
updates from destiny-gastric 01
-
3:12
advances in her2-targeted therapies for gastric cancer
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
1:08
updated survival results of destiny-breast03: t-dxd vs t-dm1 in her2 metastatic breast cancer
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
1:46
choosing between tucatinib and t-dxd in her2 breast cancer
-
1:43
gasther2: trastuzumab for advanced gastric cancer
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
5:11
destiny-breast04: t-dxd provides significant improvement in os pfs in her2-low mbc
-
0:54
targeted treatment for gastric cancer beyond her2
-
2:39
first line immunotherapy/chemotherapy in her2- gastric cancer in japan
-
6:45
trastuzumab deruxtecan for patients w/ her2-positive advanced gastric or ge junction adenocarcinoma
-
1:05
limitations in immune checkpoint inhibitors in treating gastric cancer